| Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting |
SAN JOSE, May 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Pamela D. Garzone, Chief Development Officer of Anixa, will present a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 30 – June 3, 2025, in Chicago, Illinois. |
prnewswire.com |
2025-05-12 12:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th |
SAN JOSE, Calif. , April 30, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the H.C. |
prnewswire.com |
2025-04-30 12:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for CAR-T Technology, Further Strengthening its Robust Intellectual Property Portfolio |
SAN JOSE, Calif. , April 14, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application covering its chimeric antigen receptor-T cell (CAR-T) technology. |
prnewswire.com |
2025-04-14 12:00:00 |
Czytaj oryginał (ang.) |
| ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up |
Anixa Biosciences stock jumps 13% on new patent grant for its breast cancer vaccine technology in the United States. |
zacks.com |
2025-04-10 15:00:45 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Receives Notice of Allowance from U.S. Patent and Trademark Office for Patent Covering Breast Cancer Vaccine Technology |
Patent Broadens Immunogenic Compositions for Preventive Vaccine Approach SAN JOSE, Calif. , April 9, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new patent related to the Company's innovative breast cancer vaccine technology. |
prnewswire.com |
2025-04-09 12:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences to Present at the Jones Las Vegas Healthcare and Technology Innovation Conference on April 9th |
SAN JOSE, Calif. , April 1, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the Jones Las Vegas Healthcare and Technology Innovation Conference, to be held on April 8-9, 2025, at The Venetian Resort in Las Vegas, Nevada. |
prnewswire.com |
2025-04-01 12:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Enters Letter of Intent with VERDI Solutions to Develop Artificial Intelligence-Guided Personalized and Off-the-Shelf Cancer Vaccines |
VERDI's personalized vaccines have demonstrated safety and efficacy in cancer patients SAN JOSE, Calif. , March 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a letter of intent with VERDI Solutions, GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients. |
prnewswire.com |
2025-03-25 10:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Receives Notice of Allowance from USPTO for Ovarian Cancer Vaccine |
SAN JOSE, Calif. , March 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent application covering its ovarian cancer vaccine technology. |
prnewswire.com |
2025-03-24 10:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences CEO to Present at the 2025 CAGLA NeauxCancer Conference on March 28th |
SAN JOSE, Calif. , March 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and Chief Executive Officer, Dr. Amit Kumar, will be presenting at the 2025 Cancer Advocacy Group of Louisiana ("CAGLA") NeauxCancer Conference taking place on March 27-29, 2025 at the The Roosevelt Hotel in New Orleans. |
prnewswire.com |
2025-03-17 10:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences 2025 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties |
SAN JOSE, Calif. , March 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2025 Annual Meeting of Stockholders (the "Meeting") on Thursday, March 20, 2025 at 10:00 a.m. |
prnewswire.com |
2025-03-10 10:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Announces Chief Development Officer Dr. Pam Garzone to Speak at the Alliance for Cancer Gene Therapy Summit 2025 on March 19th |
SAN JOSE, Calif. , March 3, 2025 /PRNewswire/ -- Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced Dr. Pam Garzone, Chief Development Officer of Anixa, will be attending the Alliance for Cancer Gene Therapy (ACGT) Summit 2025 and participating as a panelist on the Gynecologic and Breast Cancers panel. |
prnewswire.com |
2025-03-03 10:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences and Moffitt Cancer Center Complete Dosing in Third Cohort in Ovarian Cancer CAR-T Clinical Trial |
SAN JOSE, Calif. , Feb. 26, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced has it has dosed its final patient in the third cohort of its ongoing Phase 1 clinical trial evaluating its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. |
prnewswire.com |
2025-02-26 10:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences' Breast Cancer Vaccine was Featured on Fox News' "America Reports" |
SAN JOSE, Calif. , Feb. 25, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its breast cancer vaccine was featured on Fox News' "America Reports. |
prnewswire.com |
2025-02-25 09:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Featured in Breaking Cancer News Article on Novel CAR-T Therapy for Ovarian Cancer |
SAN JOSE, Calif. , Feb. 24, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today is pleased to announce that its pioneering CAR-T therapy for ovarian cancer, developed in collaboration with Moffitt Cancer Center ("Moffitt"), was prominently featured in Breaking Cancer News in an article titled "Navigating Uncharted Territory: CAR-T for Ovarian Cancer. |
prnewswire.com |
2025-02-24 10:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial |
Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies SAN JOSE, Calif. , Feb. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that it, along with its partner Moffitt Cancer Center ("Moffitt"), has received approval for an amendment to the protocol governing its ongoing clinical trial using CAR-T therapy for the treatment of ovarian cancer (NCT05316129). |
prnewswire.com |
2025-02-18 10:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Chairman and CEO Discusses Pioneering CAR-T Cell Therapy and Breast Cancer Vaccine in Alpha Wolf Trading Interview |
SAN JOSE, Calif. , Feb. 14, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, was featured in an interview with Alpha Wolf Trading. |
prnewswire.com |
2025-02-14 09:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences to Present at the 18th Annual European Life Sciences CEO Forum |
SAN JOSE, Calif. , Feb. 11, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Mike Catelani, President and CFO of Anixa, will be participating in the 18th Annual European Life Sciences CEO Forum taking place February 26-27, 2025, at the Hilton Zurich Airport Hotel in Zurich, Switzerland. |
prnewswire.com |
2025-02-11 10:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences' Chairman & CEO Dr. Amit Kumar Featured on CW39's H-Town Live to Discuss the Future of Breast Cancer Prevention |
SAN JOSE, Calif. , Feb. 4, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Dr. Amit Kumar, Chairman and CEO of Anixa, was featured on CW39's H-Town Live, where he discussed the Company's pioneering efforts in breast cancer prevention. |
prnewswire.com |
2025-02-04 10:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences CEO Provides Letter to Shareholders |
SAN JOSE, Calif. , Jan. 21, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today provided the following letter to shareholders from the Company's, Chairman and CEO, Dr. Amit Kumar: To our valued shareholders, I am excited to highlight our key achievements from the past year and share our upcoming goals and milestones for 2025 at Anixa Biosciences. |
prnewswire.com |
2025-01-21 10:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 |
SAN JOSE, Calif , Dec. 4, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, announced today that it will be participating in the iAccess Alpha Virtual Best Ideas Winter Conference 2024 being held on December 10th and 11th, 2024. Dr. Amit Kumar, CEO of Anixa, is scheduled to present on Tuesday, December 10 th at 2:00 p.m. |
prnewswire.com |
2024-12-04 10:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset |
SAN JOSE, Calif. , Nov. 22, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset. |
prnewswire.com |
2024-11-22 10:15:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial |
Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose SAN JOSE, Calif. , Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has dosed its first patient in the third cohort in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor-T cell (CAR-T) therapy for recurrent ovarian cancer. |
prnewswire.com |
2024-11-18 10:20:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting |
Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol defined immune responses were exhibited in over 70% of patients A Phase 2 study evaluating the vaccine in the neoadjuvant setting is planned to commence in 2025 SAN JOSE, Calif. , Nov. 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of new, updated positive data from the Phase 1 clinical trial of its breast cancer vaccine (NCT04674306) at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held in Houston, Texas. |
prnewswire.com |
2024-11-08 15:17:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting |
SAN JOSE, Calif. , Nov. 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, will be made publicly available on the Company's website at 12:15pm CT on November 8, 2024. |
prnewswire.com |
2024-11-06 10:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024 |
SAN JOSE, Calif. , Oct. 31, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its presentation at the Sidoti Micro-Cap Virtual Conference, taking place November 13-14, 2024. |
prnewswire.com |
2024-10-31 10:15:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting |
SAN JOSE, Calif. , Oct. 28, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of additional data from the Phase 1 clinical trial of its breast cancer vaccine at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held virtually and in Houston, Texas, from November 6-10, 2024. |
prnewswire.com |
2024-10-28 10:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial |
Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif. , Oct. 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has administered the second dose of its CAR-T therapy to an individual patient. |
prnewswire.com |
2024-10-15 13:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development |
SAN JOSE, Calif. , Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Suyasha Gupta as Senior Director of Clinical Development. |
prnewswire.com |
2024-10-07 12:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial |
Amendment will allow a second dose of CAR-T therapy to suitable patients SAN JOSE, Calif. , Sept. 30, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it and partner Moffitt Cancer Center ("Moffitt") have submitted an amendment to the current protocol that governs its ongoing clinical trial utilizing a CAR-T therapy to treat ovarian cancer (NCT05316129). |
prnewswire.com |
2024-09-30 12:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine |
Announces focus on therapeutic approach; resulting in a faster and more cost-effective path to approval SAN JOSE, Calif. , Sept. 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its strategic plan for a Phase 2 study for its breast cancer vaccine. |
prnewswire.com |
2024-09-24 12:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference |
SAN JOSE, Calif. , Sept. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer Research Alliance's ("OCRA") International Gynecologic Cancer Conference taking place online September 25-27, 2024. |
prnewswire.com |
2024-09-18 12:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium |
SAN JOSE, Calif. , Sept. 3, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the inventor of its ovarian cancer CAR-T technology, Jose R. |
prnewswire.com |
2024-09-03 12:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference |
SAN JOSE, Calif., Aug. 26, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that management will participate in the H.C. |
prnewswire.com |
2024-08-26 12:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting |
SAN JOSE, Calif. , July 29, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation on its ovarian cancer CAR-T therapy clinical trial at the International Gynecologic Cancer Society (IGCS) 2024 Annual Global Meeting being held October 16-18, 2024, in Dublin, Ireland. |
prnewswire.com |
2024-07-29 12:45:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy |
IND follows encouraging findings of necrosis, inflammation and T cell infiltration in tumor biopsy of patient in lowest dose cohort SAN JOSE, Calif. , July 23, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Moffitt Cancer Center (Moffitt), has received approval by the U.S. Food and Drug Administration (FDA) of an individual patient Investigational New Drug Application (IND) to allow a second dose of its CAR-T therapy for a patient that may be demonstrating clinical activity to the initial treatment. |
prnewswire.com |
2024-07-23 12:15:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology |
SAN JOSE, Calif. , July 17, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has received a "Decision to Grant" notice from the Japan Patent Office (JPO) for the patent application titled "Vaccine Adjuvants and Formulations. |
prnewswire.com |
2024-07-17 12:00:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Announces $5 Million Share Repurchase Program |
SAN JOSE, Calif. , July 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Board of Directors has authorized a share repurchase program of up to $5 million of the Company's outstanding common stock. |
prnewswire.com |
2024-07-15 12:30:00 |
Czytaj oryginał (ang.) |
| Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial |
This patient is expected to be the final patient in the second dosage cohort of the trial SAN JOSE, Calif. , June 24, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. |
prnewswire.com |
2024-06-24 12:45:00 |
Czytaj oryginał (ang.) |
| 7 Penny Biotech Stocks to Triple Your Investment |
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks. |
investorplace.com |
2024-05-28 10:10:00 |
Czytaj oryginał (ang.) |